PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23027640-2	2012	Here, we compare for the first time the relative efficacies of new-generation aminoglycosides NB30, NB54 and the chemical compound PTC124 on retinal toxicity and read-through efficacy of a nonsense mutation in the USH1C gene, which encodes the scaffold protein harmonin.	Aminoglycosides	78-93	USH1 protein network component harmonin	Homo sapiens	214-219	
24664766-4	2014	Currently only the amelioration of the hearing deficiency is implemented, but no treatment of the senso-neuronal degeneration in the eye exists.In our studies we are focusing on the evaluation of gene-based therapies to cure the retinal degeneration of USH1C patients: (i) gene augmentation using recombinant adeno-associated virus, (ii) genome editing by homologous recombination mediated by zinc-finger nucleases and, (iii) read-through therapy using novel designer aminoglycosides and PTC124.	Aminoglycosides	468-483	USH1 protein network component harmonin	Homo sapiens	253-258	
20671281-0	2010	Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina.	Aminoglycosides	65-79	USH1 protein network component harmonin	Homo sapiens	29-34	
20671281-6	2010	Here, we investigated the capability of the novel synthetic aminoglycoside NB30 for the translational read-through of the USH1C-p.R31X nonsense mutation as a retinal therapy option.	Aminoglycosides	60-74	USH1 protein network component harmonin	Homo sapiens	122-127	
20671281-14	2010	CONCLUSIONS: Commercial aminoglycosides and NB30 induced significant read-through of the USH1C-p.R31X nonsense mutation.	Aminoglycosides	24-39	USH1 protein network component harmonin	Homo sapiens	89-94